FDA's stance on compounding from bulk drugs challenged

被引:0
|
作者
不详
机构
关键词
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
引用
收藏
页码:1656 / 1657
页数:2
相关论文
共 50 条
  • [21] Development of new drugs from an FDA regulatory perspective
    不详
    CLINICAL BIOCHEMISTRY, 2004, 37 (12) : 1126 - 1126
  • [23] An ethicist's commentary on veterinarians producing autogenous vaccines and compounding antimicrobial drugs
    Rollin, BE
    CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE, 2002, 43 (03): : 164 - 164
  • [24] Overview of FDA’s Expanded Access Program for Investigational Drugs
    Jonathan P. Jarow
    Peter Lurie
    Sarah Crowley Ikenberry
    Steven Lemery
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 177 - 179
  • [25] Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs
    Frank J. Sasinowski
    Drug information journal : DIJ / Drug Information Association, 2012, 46 (2): : 238 - 263
  • [26] The FDA's Assessment of Two Drugs for Chronic Weight Management
    Colman, Eric
    Golden, Julie
    Roberts, Mary
    Egan, Amy
    Weaver, Joyce
    Rosebraugh, Curtis
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (17): : 1577 - 1579
  • [27] Overview of FDA's Expanded Access Program for Investigational Drugs
    Jarow, Jonathan P.
    Lurie, Peter
    Ikenberry, Sarah Crowley
    Lemery, Steven
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (02) : 177 - 179
  • [28] FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs
    Nambiar, Sumathi
    Walinsky, Sarah
    Schumann, Katherine
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (04) : 813 - 815
  • [29] US FDA's safety monitoring of drugs with expedited approval
    Furlow, Bryant
    LANCET ONCOLOGY, 2016, 17 (03): : 281 - 281
  • [30] India's bulk drugs sector grows up
    Tremblay, JF
    CHEMICAL & ENGINEERING NEWS, 2000, 78 (19) : 24 - +